Nagelli S et al. CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response. Trends in Cancer. 2023 Oct 2.
Link →
Oras A et al. Profiling of peripheral blood B-cell transcriptome in children who developed coeliac disease in a prospective study.
Heliyon. 2023 Jan 21;9(2):e13147.
Pubmed →
Brunell A E et al. Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities. Frontiers in Immunology. 2023 Apr 14;14:1151632.
Pubmed →
Suomi T et al. Gene expression signature predicts rate of type 1 diabetes progression.
EBioMedicine. 2023 Jun;92:104625.
Pubmed →
Moulder R et al. Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes distinguishes markers of disease and C-peptide trajectory. Diabetologia. 2023 Nov;66(11):1983-1996.
Pubmed →
Lamichhane S et al. Circulating metabolic signatures of rapid and slow progression to type 1 diabetes in islet autoantibody-positive children. Frontiers in Endocrinology. 2023 Sep 6;14:1211015.
Pubmed →
Hirvonen M K et al. Serum APOC1 levels are decreased in young autoantibody positive children who rapidly progress to type 1 diabetes. Scientific Reports. 2023 Sep 24;13(1):15941.
Pubmed →
Cazzoli R et al. Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibition. Cell Reports. 2023 Jun 7;42(6):112616. Online ahead of print.
Pubmed →
Örd T et al. Dissecting the polygenic basis of atherosclerosis via disease-associated cell state signatures. American Journal of Human Genetics. 2023.Apr 11;S0002-9297(23)00097-6.
Pubmed →
Westermarck J. Inhibition of adaptive therapy tolerance in cancer: is triplet mitochondrial targeting the key?. Molecular Oncology. 2023. Feb 28.
Pubmed →
Huuhtanen J. et al. Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients. Journal of Clinical Investigation. 2023. Jan 31;e164809.
Pubmed →
Aakula A et al. RAS and PP2A activities converge on epigenetic gene regulation. Life Science Alliance. 2023 Mar 1;6(5):e202301928.
Pubmed →
Pavic K et al. Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A. Nature Communications. 2023 Feb 28;14(1):1143.
Pubmed →
Vaparanta K et al. An extracellular receptor tyrosine kinase motif orchestrating intracellular STAT activation. Nature Communications. 2022. Nov 14;13(1):6953.
Pubmed →
Aakula A et al. PP2A methylesterase PME-1 suppresses anoikis and is associated with therapy relapse of PTEN-deficient prostate cancers. Molecular Oncology. 2022. Dec 3. Online ahead of print.
Pubmed →
de Thonel A et al. CBP-HSF2 structural and functional interplay in Rubinstein-Taybi neurodevelopmental disorder. Nature Communications. 2022. Nov 16: 13;7002.
Link to Page→
Hu WT et al. CIP2A deficiency promotes depression-like behaviors in mice through inhibition of dendritic arborization. EMBO reports. 2022. Oct 28; e54911.
Link to Page→
Peuhu E et al. MYO10-filopodia support basement membranes at pre-invasive tumor boundaries. Developmental Cell. 2022. Oct 24: 57;20.
Link to Page→
Butt U et al. SHARPIN serine 146 phosphorylation mediates ARP2/3 interaction, cancer cell invasion, and metastasis. Journal of Cell Science. 2022. Sep 23;jcs.260627. Online ahead of print.
Pubmed→
Rytkönen KT et al. Cell type markers indicate distinct contributions of decidual stromal cells and natural killer cells in preeclampsia. Reproduction. 2022. Sep 1;REP-22-0079.
Pubmed→
Mohd Moin Khan et al. Long Intergenic Noncoding RNA MIAT as a Regulator of Human Th17 Cell Differentiation. Frontiers in Immunology. 2022. Jun 15;13:856762.
Pubmed→
